Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
08:00am, Thursday, 08'th Feb 2024
BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd Feb 2024
BRIDGEWATER, N.J. , Feb. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
10:34am, Thursday, 26'th Oct 2023
Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.
Why Shares of Insmed Are Soaring This Week
02:09pm, Friday, 08'th Sep 2023
Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
09:03am, Wednesday, 06'th Sep 2023
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
Insmed stock climbs on positive study results; hits 52-week high
03:52pm, Tuesday, 05'th Sep 2023
Insmed Incorporated (NASDAQ:INSM) shares jumped 18% to $26.62 after the biopharmaceutical company revealed that nearly 44% of patients with nontuberculous mycobacterial (NTM) lung infection in its
Why Insmed Stock Is Soaring Today
11:52am, Tuesday, 05'th Sep 2023
Insmed reported positive top-line results from a late-stage study of its antibiotic drug Arikayce. The data could improve the likelihood of success in another late-stage study of Arikayce.
Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript
12:23am, Sunday, 06'th Aug 2023
Insmed Incorporated (NASDAQ:INSM ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bryan Dunn - Head, IR William Lewis - Chair & CEO Sara Bonstein - CFO Martina Flammer
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
06:02pm, Friday, 28'th Jul 2023
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will d
Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
08:00am, Wednesday, 07'th Jun 2023
BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Insmed Incorporated (INSM) Q1 2023 Earnings Call Transcript
06:21pm, Saturday, 06'th May 2023
Insmed Incorporated (NASDAQ:INSM ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bryan Dunn - Head of Investor Relations Will Lewis - Chair and Chief Executive Officer Sa
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Thursday, 04'th May 2023
Insmed (INSM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $0.80 per share a year ago.
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstruc
Insmed Incorporated (INSM) Q4 2022 Earnings Call Transcript
05:20pm, Thursday, 23'rd Feb 2023
Insmed Incorporated (NASDAQ:INSM ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chair and CEO Sara Bonstein - CFO Conference Ca
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
10:32am, Thursday, 23'rd Feb 2023
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
